Veracyte will present over 15 studies on its Decipher prostate and bladder cancer tests, including new clinical trial data, at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco.
New Labcorp survey of 152 oncologists reveals 89% expect care to become more complex within three years, while digital integration and coverage barriers persist.
The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.
CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.
Read More
The collaboration will combine New Day’s liquid biopsy technology with Daisy Genomics’ physics-based sequencing platform to advance early CRC screening.
Read More
Multi-year agreement will provide clinical workflow software and laboratory support for GlycoKnow liquid biopsy test.
Read More
New guidelines designate high-risk HPV testing as preferred screening method for women ages 30-65 and require insurance coverage for additional testing.
Read More
The biotechnology company’s integrated screening approach combines whole-genome sequencing, imaging, and multiple biomarker tests to enable early detection.
Read More
Three abstracts showcase PreciseBreast’s ability to predict recurrence risk in early-stage invasive breast cancer using digital pathology.
Read More
Despite effective prevention tools, Millennials are delaying screening. New approaches may help remove barriers to participation.
Read More
Study in biliary tract cancer finds the solution achieved 83.5% overall concordance rate with expert interpretations.
Read More
Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
Read More
A genomic test widely used in prostate cancer care can more accurately identify which men with early-stage disease face high risk of recurrence after treatment.
Read More
Better cancer testing can help patients avoid unnecessary scans and biopsies, while also lowering costs for the healthcare system.
Read More
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.
Read More
New diagnostic chip pulls packets released from tumor cells out of blood, showing whether cancer cells died during chemotherapy infusion.
Read More
Two peer-reviewed studies demonstrate superior risk stratification compared to traditional clinicopathologic features and competitor testing.
Read More
The test can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for Enhertu.
Read More